Comparison of the Effects of Pioglitazone vs. Placebo When Given in Addition to Standard Insulin Treatment in Patients With Type 2 Diabetes Mellitus and Renal Failure.
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2013
At a glance
- Drugs Pioglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms PIOren
- Sponsors Takeda Pharma
- 10 Jun 2017 Biomarkers information updated
- 21 Apr 2012 Planned number of patients changed from 40 to 100 as reported by European Clinical Trials Database record.
- 21 Apr 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2007-006744-21).